Drug Trial Radar · NCT05333458
Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
27
Planned (sponsor's estimate)
Start
Aug 29, 2022
Primary completion
May 1, 2027
Study completion May 1, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Apr 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial tests whether atezolizumab in combination with selinexor works to shrink tumors in patients with alveolar soft part sarcoma and whether the study drugs are better than the usual approach in treating this type of cancer. The usual approach is defined as care most people get for alveolar soft part sarcoma if they are not part of a clinical study, which includes treatment with radiation, kinase inhibitor drugs, immunotherapy drugs, or chemotherapy drugs. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by blocking a protein called CRM1, which may help keep cancer cells from growing and may kill them. Giving atezolizumab in combination with selinexor may help shrink tumors and stabilize the cancer in patients with alveolar soft part sarcoma.
Conditions
- Advanced Alveolar Soft Part Sarcoma
- Advanced Soft Tissue Sarcoma
- Metastatic Alveolar Soft Part Sarcoma
- Refractory Alveolar Soft Part Sarcoma
- Unresectable Alveolar Soft Part Sarcoma
Interventions
AtezolizumabBiological
Given IV
Biopsy ProcedureProcedure
Undergo biopsy
Biospecimen CollectionProcedure
Undergo collection of blood samples
Computed TomographyProcedure
Undergo CT
Echocardiography TestProcedure
Undergo ECHO
SelinexorDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rateTime frame: Within first 12 cycles of treatment confirmed 4-8 weeks later (Each cycle = 28 days)
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Keck Medicine of USC Koreatown
Los Angeles, California · Recruiting
Los Angeles General Medical Center
Los Angeles, California · Recruiting
USC / Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut · Recruiting
Yale University
New Haven, Connecticut · Recruiting
Smilow Cancer Hospital Care Center-Trumbull
Trumbull, Connecticut · Recruiting
MedStar Georgetown University Hospital
Washington D.C., District of Columbia · Recruiting
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland · Recruiting
National Institutes of Health Clinical Center
Bethesda, Maryland · Active not recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
UT MD Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.